Table 1.
Baseline clinical characteristics.
| Clinical Characteristic | Soluble Fibre Group (n = 17) | Control Group (n = 12) | p * |
|---|---|---|---|
| Gender Male n (%) | 7 (41) | 6 (50) | 0.716 |
| Female n (%) | 10 (59) | 6 (50) | |
| Age (years) | 42.1 ± 3.4 | 40.4 ±4.6 | 0.770 |
| BMI (kg/m2) | 24.9 ± 0.7 | 26.6 ± 0.7 | 0.099 |
| Ex-smokers n (%) | 6 (35) | 3 (25) | 0.694 |
| ACQ-7 (units) | 0.7 ± 0.1 | 0.7 ± 0.2 | 0.941 |
| Atopy n (%) | 14 (82) | 8 (67) | 0.403 |
| AHR n (%) | 10 (59] | 5 (41.7) | 0.462 |
| DRS (%∆FEV1/mL), med [IQR] | 2.2 [0.4, 6.4] | 0.6 [0.2, 2.4] | 0.109 |
| ICS dose † (μg/day), med [IQR] | 1000 [400, 1000] | 1000 [563, 1000] | 0.679 |
Data are means ± SEM unless otherwise stated. BMI: body mass index; ACQ: 7-item asthma control questionnaire; AHR: airway hyperresponsiveness; DRS: dose–response slope (% fall in forced expiratory volume in one second (FEV1)/mL saline); ICS: inhaled corticosteroids. * Difference between soluble fibre and control groups. † Beclomethasone equivalents.